Table 2.
Peptides and peptidomimetics in commercial development
| Company | Drug | Stage of development | Medical use |
|---|---|---|---|
| AM-Pharma (Bunnik, The Netherlands) | hLF-1-11 | Phase II | Allogeneic bone marrow stem cell transplantation-associated infections |
| BioLineRx Ltd (Jerusalem, Israel) | BL2060 | Preclinical | Gram-negative pneumonia |
| Ceragenix (Denver, Colorado, USA) | CSA-13 a /CGX313 | Preclinical | Prevention of nasal carriage of Staphylococcus |
| Helix Biomedix (Bothell, Washington, USA) | Lipohexapeptide | Preclinical | Anti-infective |
| Inimex (Burnaby, British Columbia, Canada) | IMX942 | Preclinical | Immunomodulation; treatment of fevers and neutropaenia in chemotherapy patients |
| Migenix Inc. (Vancouver, British Columbia, Canada) | CPI/MX-226 | Phase IIIb | Prevention of catheter-related infections |
| CLS001 | Phase II+ | Inflammation in Rosacea | |
| Novozymes A/S (Bagsvaerd, Denmark) | Plectasin | Preclinical | Systemic anti-Gram positive, especially pneumococcal infections |
| Pacgen (Vancouver, British Columbia, Canada) | PAC113 | Phase IIb | Oral candidiasis |
| Polymedix (Radnor, Philedelphia, USA) | PMX30063 b | Phase I | Systemic anti-infective peptidomimetic |
a
A cationic steroid antibiotic.
b
Non-peptidic structural analogue of an antimicrobial peptide.
This is a listing of known antimicrobial and/or immunomodulatory agents in development and/or clinical trials within private companies. Only agents currently in clinical trials or likely to enter the clinic soon are recorded. This information is based on a prior review,3 updated by us primarily from company press releases and public presentations. Several peptides that went through clinical trials but were not approved3 or polymyxins and gramicidin S that are generic anti-infectives that have long been available are not described